The USFDA has approved atogepant for use in adults, making it the first and only approved oral antagonist to avoid both episodic and chronic migraine. People suffering from migraine experience headaches for 15 or more days every month, with at least eight days associated with migraine. The new drug has aided in preventing and reducing the daily burden of migraine, providing patients with a new, safe, and effective option available in the form of a once-daily pill.
Study Phase 3 PROGRESS trial for a duration of 12 months 60 mg once daily of the drug atogepant was evaluated in adults with chronic migraine. Primary endpoint - Significant reduction in mean monthly migraine days from baseline compared to placebo Secondary endpoint - Significant results were observed in all the six secondary endpoints chosen, which included the proportion of patients with at least a 50% reduction in mean…
